TuHURA Biosciences' Pioneering Research on the Delta Opioid Receptor
TuHURA Biosciences, Inc. (NASDAQ: HURA), an innovative immune-oncology company, has made significant strides in its research into the Delta Opioid Receptor (DOR) and its implications in cancer treatment. The recent findings demonstrate that the DOR is expressed on myeloid-derived suppressor cells (MDSCs), unveiling a promising target for overcoming resistance in cancer immunotherapy.
Significance of DOR in Tumor-Associated Myeloid Cells
For the first time, it has been shown that DOR is present on tumor-associated macrophages (TAMs) and MDSCs, crucial components of the immune system that help regulate inflammation and autoimmunity. By inhibiting the DOR, TuHURA researchers have uncovered methods to reprogram the immunosuppressive functions of these cells, indicating an opportunity to enhance the effectiveness of existing immunotherapies.
Collaboration and Discoveries
This groundbreaking research is the result of a collaboration between TuHURA scientists and The Moffitt Cancer Center. Together, they highlighted the role of DOR in MDSCs sourced from patients with myeloid dysplastic syndrome (MDS), particularly noting how DOR inhibition can restore stem cell proliferation.
Oral Presentation at ASH Annual Meeting
The compelling results of this study were selected for an oral presentation at the prestigious 67th American Society of Hematology (ASH) Annual Meeting and Exposition, scheduled for December 6-9, 2025. During this meeting, TuHURA will showcase updated findings alongside a poster presentation illustrating the effects of DOR inhibition on TAMs, which are vital to the tumor microenvironment.
Details of the Oral Presentation
The oral presentation, titled Delta Opioid Receptor (DOR) Expression on Myeloid-Derived Suppressor Cells (MDSCs) Represents a Novel Target to Overcome Resistance to Immune Checkpoint Inhibitors (ICIs), will take place on December 7, 2025. Mike Turner, Ph.D., Vice President of Immunology at TuHURA, will be the presenter.
Poster Presentation Highlights
In addition to the oral presentation, TuHURA will present research findings in a poster format titled Delta Opioid Receptor (DOR): A Novel Target for Reprogramming Tumor-Associated Macrophage (TAM) Immunosuppressive Phenotype to Overcome Acquired Resistance and Enhance the Effectiveness of Cancer Immunotherapies on December 6, 2025. Krit Ritthipichai, D.V.M., Ph.D., Director of Immunology at TuHURA Biosciences, will lead this presentation.
Ongoing Research and Future Directions
In the broader scope of ongoing research, TuHURA's collaboration with The Moffitt Cancer Center extends to exploring the pathogenic attributes of DOR-expressing MDSCs in patients. This continues to affirm the hypothesis that DOR antagonism could present an effective strategy deserving deeper clinical investigation.
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (NASDAQ: HURA) is dedicated to developing innovative solutions to address challenges surrounding primary and acquired resistance in cancer therapies. One of their leading products is IFx-2.0, an innate immune agonist designed to enhance the efficacy of checkpoint inhibitors. Currently, TuHURA is conducting a randomized Phase 3 registration trial of IFx-2.0 in conjunction with Keytruda (pembrolizumab) for advanced Merkel Cell Carcinoma treatment.
Expanding Product Portfolio
Additionally, following a merger with Kineta Inc., TuHURA has acquired TBS-2025, aimed at progressing into Phase 2 trials targeting VISTA in refractory acute myeloid leukemia (AML). This strategic expansion signifies TuHURA's commitment to harnessing DOR technology and other assets to develop first-in-class immuno-oncology therapies.
Frequently Asked Questions
What is the main focus of TuHURA Biosciences' recent research?
The focus is on the Delta Opioid Receptor (DOR) and its role in myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) in cancer immunity.
Where will the findings be presented?
The findings will be presented at the 67th American Society of Hematology (ASH) Annual Meeting in December 2025.
Who is leading the oral presentation?
Mike Turner, Ph.D., Vice President of Immunology at TuHURA, will lead the oral presentation.
What is the significance of DOR inhibition?
DOR inhibition has shown potential to reprogram the immunosuppressive mechanisms within the tumor microenvironment, potentially enhancing the effectiveness of cancer treatments.
What are TuHURA's future product plans?
TuHURA aims to leverage its discoveries around the DOR to develop novel antibody drug conjugates and immune-modulating therapies to combat cancer more effectively.
